Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SWITCH-AF: Warfarin vs DOAC in AF with Recent Stroke
NCT07011095Phase 1Not yet recruiting
- Sponsor
- Population Health Research Institute
- Start
- Sep 2025
- Primary completion
- Feb 2027
- Modality
- Small Molecules
01
Overview
Phase 1, randomised, open-label trial of warfarin in Atrial fibrillation (AFib) (2 arms), sponsored by Population Health Research Institute. Primary endpoint: Feasibility - Recruitment at 24 months. Planned start Sep 2025; status: not yet recruiting.
02
Drugs
warfarin
03
Conditions
Atrial fibrillation (AFib)
Beyond the preview
Go deeper on NCT07011095.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07011095.